๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shanghai
Clinical trial register · China

Clinical Trials in Shanghai, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 21 Shanghai 15 Guangzhou 14 Fuzhou 7 Changchun 6
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing21 Shanghai15 Guangzhou14 Fuzhou7 Changchun6
All 48 locations
Target enrolment
to

Trials with a site in Shanghai

15 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission
NCT07507318Diffuse Large B-Cell Lymphoma
Rong Tao
Phase 2
69
Shanghai
2026-06-16
Recruiting
Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PET
NCT07070648Diffuse Large B-Cell Lymphoma, DLBCL
Fudan University
Observational
300
Shanghai
2025-05-09
Recruiting
Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL
NCT06803693Diffuse Large B-Cell Lymphoma
Ruijin Hospital
Phase 2
152
Shanghai
2025-04-01
Recruiting
Autologous Hematopoietic Stem Cell Boost Study After CAR-T Therapy
NCT06589089Diffuse Large B Cell Lymphoma
Ruijin Hospital
Phase 2
18
Shanghai
2024-10-15
Recruiting
Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)
NCT06517511Diffuse Large B Cell Lymphoma
Sun Yat-sen University
Phase 2
42
Guangzhou, Shanghai
2024-08-01
Recruiting
The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma
NCT06522555Diffuse Large B-Cell Lymphoma
Ruijin Hospital
Phase 3
100
Shanghai
2024-07-29
Recruiting
PET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell Lymphoma
NCT06755775Diffuse Large B-Cell Lymphoma
Ruijin Hospital
Observational
150
Shanghai
2024-07-23
Recruiting
An Open-label, Single-arm Study of JWCAR201 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
NCT06517004Diffuse Large B Cell Lymphoma
Fudan University
Phase 1
9
Shanghai
2024-07-18
Active, closed
A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)
NCT05192486Diffuse Large B-cell Lymphoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
12
Shenzhen, Baoding, Luoyang, Shanghai
2022-08-10
Recruiting
Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma
NCT05348213Diffuse Large B Cell Lymphoma
Ruijin Hospital
Phase 2
76
Shanghai
2022-05-16
Recruiting
R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse
NCT05257018Diffuse Large B-cell Lymphoma
Fudan University
Phase 2
83
Shanghai, รœrรผmqi
2022-02-26
Recruiting
The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk
NCT05018520Diffuse Large B Cell Lymphoma
Ruijin Hospital
Phase 3
640
Shanghai
2021-09-17
Active, closed
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT04408638Diffuse Large B-cell Lymphoma
Hoffmann-La Roche
Phase 3
270
Beijing, Guangzhou, Harbin, Shanghai, Tianjin, Wuhan, Zhejiang, Zhengzhou
2021-02-23
Active, closed
Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL)
NCT04460248Diffuse Large B Cell Lymphoma
Ruijin Hospital
Phase 2
40
Shanghai
2020-08-26
Rows per page Showing 1–15 of 15
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/shanghai

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 15 of those studies with a site in Shanghai that also match the filters currently applied.

How many clinical trials are recruiting in Shanghai?

12 of the 15 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 0 have not yet opened recruitment, 3 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Shanghai), 15 studies
PhaseStudiesRecruitingShare
Phase 28753.3%
Phase 33220%
Observational2213.3%
Phase 1116.7%
Phase 1/2106.7%

Most active sponsors

Lead sponsors with the most studies (Shanghai)
Lead sponsorStudiesRecruiting
Ruijin Hospital76
Fudan University44
Hoffmann-La Roche10
Rong Tao11
Sichuan Baili Pharmaceutical Co., Ltd.10
Sun Yat-sen University11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.